List of Excipients in API dapagliflozin saxagliptin and metformin hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing dapagliflozin saxagliptin and metformin hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | QTERNMET | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 | ANHYDROUS LACTOSE | 2031-05-12 |
| AstraZeneca Pharmaceuticals LP | QTERNMET | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 | CELLULOSE, MICROCRYSTALLINE | 2031-05-12 |
| AstraZeneca Pharmaceuticals LP | QTERNMET | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 | CROSCARMELLOSE SODIUM | 2031-05-12 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for dapagliflozin saxagliptin and metformin hydrochloride
Excipient focus: ANHYDROUS LACTOSE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2208
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
dapagliflozin saxagliptin and metformin hydrochloride drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin saxagliptin and metformin hydrochloride | 0310-6925 |
| >Company | >Ingredient | >NDC |
dapagliflozin saxagliptin and metformin hydrochloride drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links